Cure the Incurable – Cell and Gene Therapy to Revolutionize Medicine

At the 2024 Lund University Foundation Convocation in New York, leading researchers from Sweden and the United States, discussed how Advanced Therapy Medicinal Product (ATMP) can Cure the Incurable. ATMP is a specialized class of medicine for human use that relies on genes, cells, or tissue engineering rather than traditional chemical synthesis.

Cell and Gene Therapy is a groundbreaking research area with the potential to cure diseases that are currently incurable. This approach involves replacing dead or injured cells with new, healthy ones, correcting mutated genes, or redirecting the functions of existing cells. Promising preclinical and early clinical data from first-in-human trials of these novel therapies will be presented, showcasing fantastic results. The presentations will be followed by discussion and Q&A.

Panel

Anna Falk, Professor and Director of LU-ATMP* Center, Lund University
Johan Flygare, Associate Professor and Coordinator of the national ATMP research school, Co-director of Lund Stem Cell Center, Lund University
Filipe Pereira, Professor at Lund University and ATMP entrepreneur
Michel Sadelain, MD, PhD, Director of the Columbia Initiative in Cell Engineering and Therapy, Columbia University, New York, NY
Stefan Irion, MD, CSO of BlueRock Therapeutics

The 2024 LUF Convocation

The event was organized by Lund University in collaboration with Lund University Foundation and the Consulate General of Sweden in New York.